Search Results
396 results found for "Domain Therapeutics"
Programs (1)
- Applying Pharmacology to Drug Discovery
What makes each drug type unique to therapeutic pharmacology? 3.
Posts (280)
- Domain Therapeutics Raises $42m Series A Financing
development of its best-in-class and first-in-class immuno-oncology programs STRASBOURG, France & MONTREAL- Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative
- Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal for ...
April 2022 Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal and CEO: Gyo Sagara; “Ono”) today announced that it has newly signed a collaboration agreement with Domain Therapeutics S.A. (Strasbourg, France; CEO: Pascal Neuville; “Domain”) and Université de Montréal (Québec, Canada; “UdM
- Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology
March 2022 "Explicyte grants Domain Therapeutics exclusivity on data related to GPCR implicated in immunoresistance Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing their expertise to identify GPCR targets and associated biomarkers to discover and develop breakthrough therapeutic
Other Pages (113)
- Ep 81 with Dr. Christel Menet
I then started my career at Evotec before moving to Domain Therapeutics (called Faust pharmaceutical chemistry. 6 years ago I decided to take on a new challenge by taking the position of CSO at Confo Therapeutics Christel Menet on the web Hyphen Projects GPCRS Drug Discovery Confo Therapeutics LinkedIn Dr.
- Session III | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
This gap is due to their unique autoproteolytic cleavage in the GAIN domain, creating a heterodimer of technology for high-throughput screening of pharmacological compound libraries to identify potential therapeutic Therapeutics North America Inc, Montréal, Québec, Canada (2) Department of Pharmacology-Physiology, Laurent Sabbagh on the web Domain Therapeutics Characterizing hADGRE5/CD97 Activation and Signaling: Domain Therapeutics North America Inc., Montreal, Quebec, Canada 3.
- Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Vulnerability in Ovarian Cancer
Sponsors GPCR Retreat Program < Back to schedule Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Several of these targets are being developed for potential new therapeutic strategies in ovarian and GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec
Events (2)
- Practical Quantification of Allosteric ModulationTickets: $0.00May 1, 2025 | 2:00 PM
- Development of GPCR Ligands as Therapeutic DrugsTickets: $0.00March 20, 2025 | 2:00 PM